UBS Maintains Neutral on Humana, Lowers Price Target to $250
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Kevin Caliendo maintains a Neutral rating on Humana (NYSE:HUM) and lowers the price target from $380 to $250.
October 04, 2024 | 7:13 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
UBS analyst Kevin Caliendo has maintained a Neutral rating on Humana and significantly lowered the price target from $380 to $250, indicating a less optimistic outlook.
The significant reduction in the price target from $380 to $250 by UBS suggests a less favorable view on Humana's future performance, which could lead to a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100